CHMP Backs Lonoctocog Alfa (Afstyla) for Hemophilia A CHMP Backs Lonoctocog Alfa (Afstyla) for Hemophilia A
A European Medicines Agency committee has recommended marketing authorization for lonoctocog alfa for the prevention and treatment of bleeding in patients of all ages with hemophilia A.International Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
More News: Bleeding | Cancer & Oncology | European Medicines Agency (EMA) | Haemophilia | Hematology | Hemophilia | Marketing